In its first license agreement for small-molecule compounds, Emisphere Technologies Inc. signed on with F. Hoffmann-La Roche Ltd. to develop oral formulations of approved therapies for bone-related diseases. (BioWorld Today)

Stressgen's HspE7 Positive In Cervical Dysplasia Study

Nov. 18, 2004

By Karen Carey

Demonstrating a 40 percent response rate in high-grade cervical dysplasia patients, Stressgen Biotechnologies Corp.'s lead candidate, HspE7, appears to be heading toward another Phase III trial. (BioWorld Today)

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
Alicorn synthesizes new AAK1 inhibitors
BioWorld Science
Researchers from Alicorn Pharmaceutical Co. Ltd. and Jiangsu Alicorn Pharmaceutical Co. Ltd. have disclosed crystalline salts of compounds acting as...
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research
BioWorld Science
Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...
Saniona reports preclinical data for SAN-2668
BioWorld Science
Saniona AB has presented preclinical data and its clinical development strategy for its lead clinical candidate, SAN-2668, which is a GABA-A receptor positive...